Published Papers KPC-34 Kucera Paper A novel phospholipid gemcitabine conjugate is able to bypass three drug-resistance mechanisms Kucera Paper Lipid Nucleoside Conjugates for the Treatment of Cancer Kucers & Pardee Paper Improving Nucleoside Analogs via Lipid Conjugation Short Summary of KPC34 The Phospholipid Gemcitabine Conjugate, KPC34, is a Novel Treatment for Leukemia Wake Forest School of Medicine Study Phospholipiddeoxycytidine analogue prodrugs for the treatment of cancer DHA-dFdC Short-term Toxicity Study of DHA-dFdC Study of DHA-dFdC Synthesis and Cytotoxic Activity of Two Novel 1-Dodecylthio-2-decyloxypropyl-3-phosphatidic Acid Conjugates with Gemcitabine and Cytosine Arabinoside
